Latest news
Meet CILcare-CBSET at the Safety Pharmacology Society annual meeting in Brussels
This year, CILcare is exhibiting with its US partner CBSET at the annual meeting of the Safety Pharmacology Society in Brussels, Belgium on September 18-21. Come to our booth #506 to learn more about our ototoxicity services and our expertise in in vitro, ex vivo, and...
CILcare to attend the IEB in London and give a presentation on cochlear synaptopathy preclinical and clinical research at the Hearing Therapeutics Summit
58th Inner Ear Biology workshop CILcare is glad to announce that its R&D team will be attending the 58th Inner Ear Biology workshop in London, UK, on September 3-5, 2023, hosted by the UCL Ear Institute. This year the event will focus on the genetics, pathology...
CILcare featured in EACCNY’s “Future of Technology” podcast
The sixth episode of the fourth season of the Future of Technology podcast, presented by the European American Chamber of Commerce of New-York in collaboration with CILcare, brings you an insightful discussion with Dr. Keith Darrow, a distinguished member of CILcare's...
CILcare, a catalyzer for therapeutic development in auditory-related disorders
CILcare is a biotech company dedicated to harnessing its unique expertise in auditory sciences to enable the early and specific detection of neurocognitive and inflammatory diseases. CILcare’s proprietary pipeline focuses on synaptopathy, a disease affecting cochlear synapses and nerve fibers. Cochlear synaptopathy is clinically characterized by a lack of intelligibility in noisy environments, considered as the early signs of age-related hearing loss and aggravated by noise exposure.
Committed to its mission of accelerating the development of novel therapies for ear disorders, CILcare has built a unique smart R&D platform to offer external innovation to its partners. Based on an unmatched expertise in preclinical otology, CILcare has supported, worldwide, top hearing research companies, biotech, pharma and academic institutions in their various development stages.
With hearing labs established in Montpellier, France, and Lexington, MA, in partnership with CBSET, a biomedical translational research center, CILcare provides comprehensive preclinical programs including: drug screening on otic cell lines, cochlear explants studies, GLP-ototoxicity, inner ear pharmacokinetics, histology of the cochlea and vestibular systems, intra-cochlear deliveries, micro-surgery, micro-pump implantation, noise-induced, drug-induced, age-related, disease-related efficacy models in mice, rats, guinea pigs, tolerance and ototoxicity with state-of-the art auditory assessment with electrophysiology, electroacoustics and behavioral tests, gene transduction in the inner ear, transtympanic injections, cell grafts, …
Testimonials

Pharma / Biotech

Medtech

Nutraceutical

Veterinary
Hearing disorders: a high unmet medical need
young people at risk of hearing loss
Disabling hearing loss could affect 2.5 billion people globally by 2050 according to the WHO. In 2019, 1.6 billion people were affected. This alarming and rapidly growing prevalence mainly results from population growth and aging, modern lifestyles with excessive noise exposure, the intake of ototoxic drugs, and chronic ear infections.
Hearing loss has been ranked as the fourth highest cause of disability worldwide, higher than many other chronic diseases including diabetes, dementia, and chronic obstructive pulmonary disease. Deafness profoundly affects the quality of life of patients and is strongly linked to cognitive decline in the elderly. Unaddressed hearing loss costs countries an estimated US$ 1 trillion annually, therefore posing a significant issue to our health systems.
A hundred pharmaceutical and biotechnology companies and thousands of academics are contributing to scientific progress in the auditory field. Although no drugs have been approved by authorities to treat hearing loss and tinnitus yet, some actors are reporting promising scientific research results. These hold the promise of filling an unmet medical need and having transformative impacts on patient populations in the near future.